Trials / Completed
CompletedNCT01181141
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DU-176b (edoxaban) | |
| DRUG | Enoxaparin sodium 20mg |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-08-01
- Completion
- 2010-02-01
- First posted
- 2010-08-13
- Last updated
- 2019-03-05
- Results posted
- 2015-01-26
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01181141. Inclusion in this directory is not an endorsement.